Market News

Today, Tokyo Stock Exchange, Inc. (TSE) approved the listing of Acucela Inc, a Seattle biotechnology company specializing in ophthalmology field, on Mothers (Market of the high-growth and emerging stocks). Acucela Inc. will be listed on Thursday, February 13, 2014. Please see attached PDF for details.

About Acucela Inc.
Acucela is a Seattle based clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela focuses on developing oral products based on Acucela’s proprietary visual cycle modulation, or VCM, compounds to address a variety of retinal diseases, primarily age-related macular degeneration, or AMD, diabetic retinopathy, or DR, and diabetic macular edema, or DME, and potentially Stargardt disease, retinitis pigmentosa and retinopathy of prematurity. Acucela is also in the early stages of developing a therapy for the treatment of glaucoma.

Outline